Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with Non-critical COVID-19: A Single-center, Retrospective, Propensity Score-matched Study
Uyaroğlu et al.,
Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin in the Treatment of Patients with..,
Acta Medica, doi:10.32552/2022.ActaMedica.719
PSM retrospective 260 late stage hospitalized COVID-19 pneumonia patients in Turkey, showing no significant difference between favipiravir and HCQ.
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 42 (2.4%), control 0 of 42 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
|
risk of ICU admission, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 42 (0.0%), control 1 of 42 (2.4%), NNT 42, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
hospitalization time, 9.8% lower, relative time 0.90, p = 0.90, treatment 42, control 42.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Uyaroğlu et al., 17 Mar 2022, retrospective, propensity score matching, Turkey, peer-reviewed, 6 authors, study period 20 March, 2020 - 30 September, 2020, this trial compares with another treatment - results may be better when compared to placebo.
Contact:
oguzuyaroglu@hotmail.com.
Abstract: Acta Medica 2022; 53(1): 73-82
acta medica
ORIGINAL ARTICLE
Comparison of Favipiravir to Hydroxychloroquine Plus Azithromycin
in the Treatment of Patients with Non-critical COVID-19: A Singlecenter, Retrospective, Propensity Score-matched Study
Oğuz Abdullah Uyaroğlu1
ORCID: 0000-0003-0440-2026
Meliha Çağla Sönmezer2
ORCID: 0000-0001-6529-5282
Gülçin Telli Dizman2
ORCID: 0000-0001-8195-3345
Nursel Çalık Başaran1
ORCID: 0000-0002-1290-6905
Sevilay Karahan3
ORCID: 0000-0002-8692-7266
Ömrüm Uzun2
ORCID: 0000-0003-4721-0139
Hacettepe University Faculty of Medicine, Department
of Internal Medicine, Section of General Internal
Medicine, Ankara, Turkey.
1
Hacettepe University Faculty of Medicine, Department
of Clinical Microbiology and Infectious Disease, Ankara,
Turkey.
2
Hacettepe University Faculty of Medicine, Department
of Biostatistics, Ankara, Turkey.
ABSTRACT
Objectives: In this study, we compared the clinical outcomes and effects
of the treatments on laboratory parameters between patients who were
treated with favipiravir (FAV) or hydroxychloroquine plus azithromycin
(HCQ/AZ) for COVID-19 pneumonia in non-Intensive Care Unit (non-ICU)
patients.
Methods: We collected data of 260 moderate or severe COVID-19
patients hospitalized in COVID-19 wards between March 20, 2020, and
September 30, 2020 retrospectively. We used propensity score matching
to evaluate treatment effect on laboratory parameters of COVID-19
infection.
Results: We compared 42 patients using FAV and 42 HCQ/AZ after
propensity score matching. While there were statistical differences
between the therapy groups in terms of transfer to ICU and/or exitus
before matching (p=0.031), this was not significant after propensity
analysis (p=0.250). Patients treated with FAV stayed in the hospital
nearly one more day than HCQ/AZ group but the difference was not
statistically significant (9.02 days vs 8.14 days, p=0.903). The levels of
AST,ALT, and LDH increased at discharge in both groups, especially in
the FAV group.
Conclusions: FAV is not superior to HCQ/AZ in the treatment of COVID-19
infection in hospitalized patients with pneumonia.
3
Keywords: COVID-19, hydroxychloroquine, azithromycin, favipiravir,
propensity-matched analysis
Corresponding Author: Oğuz Abdullah Uyaroğlu
Hacettepe University Faculty of Medicine, Department
of Internal Medicine, Section of General Internal
Medicine, Ankara, Turkey.
E-mail: oguzuyaroglu@hotmail.com
Received: 15 December 2021, Accepted: 25 January 2022,
Published online: 10 March 2022
© 2022 Acta Medica.
73
Favipiravir Against Hydroxychloroquine Plus Azithromycin
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit